Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.
Recent advances in immunotherapy have revolutionized the treatment of breast and gynecological cancers, and current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback